XML 47 R33.htm IDEA: XBRL DOCUMENT v3.23.3
Segment Data (Tables)
 12 Months Ended
Sep. 30, 2023
Segment Reporting [Abstract]  
Revenue from External Customers by Geographic Areas
Financial information for the Company’s segments is detailed below. The Company has no material intersegment revenues.
(Millions of dollars)202320222021
United StatesInternationalTotalUnited StatesInternationalTotalUnited StatesInternationalTotal
Medical
Medication Delivery Solutions$2,519 $1,774 $4,293 $2,483 $1,825 $4,308 $2,253 $1,848 $4,101 
Medication Management Solutions2,303 677 2,980 1,935 598 2,533 1,863 570 2,432 
Pharmaceutical Systems666 1,563 2,229 533 1,468 2,001 428 1,400 1,828 
Total segment revenues$5,488 $4,014 $9,502 $4,950 $3,891 $8,841 $4,544 $3,817 $8,361 
Life Sciences
Integrated Diagnostic Solutions$1,774 $1,850 $3,624 $2,190 $1,995 $4,185 $2,477 $2,748 $5,225 
Biosciences603 906 1,509 542 838 1,379 503 802 1,305 
Total segment revenues$2,377 $2,756 $5,133 $2,732 $2,833 $5,564 $2,980 $3,550 $6,530 
Interventional
Surgery $1,159 $338 $1,497 $1,094 $306 $1,400 $1,023 $274 $1,296 
Peripheral Intervention1,016 849 1,865 960 799 1,759 931 780 1,711 
Urology and Critical Care1,073 301 1,374 986 319 1,305 894 338 1,232 
Total segment revenues$3,247 $1,489 $4,736 $3,040 $1,424 $4,464 $2,847 $1,392 $4,239 
Total Company revenues from continuing operations$11,113 $8,258 $19,372 $10,722 $8,148 $18,870 $10,371 $8,760 $19,131 
Financial Information for Company's Segments The following tables provide a reconciliation of segment operating income to Income from Continuing Operations before Income Taxes and segment information for both capital expenditures and depreciation and amortization.
(Millions of dollars)202320222021
Income from Continuing Operations Before Income Taxes
Medical (a) (b) $1,967 $2,215 $1,985 
Life Sciences1,585 1,710 2,391 
Interventional 1,217 1,081 933 
Total Segment Operating Income
4,769 5,006 5,311 
Acquisition-related integration and restructuring expense(313)(173)(179)
Net interest expense(403)(382)(460)
Other unallocated items (c)(2,391)(2,668)(2,981)
Total Income from Continuing Operations Before Income Taxes$1,662 $1,783 $1,692 
Capital Expenditures
Medical$563 $602 $740 
Life Sciences139 213 297 
Interventional138 130 125 
Corporate and All Other35 28 32 
Total Capital Expenditures$874 $973 $1,194 
Depreciation and Amortization
Medical$1,199 $1,144 $1,097 
Life Sciences277 283 352 
Interventional799 789 769 
Corporate and All Other13 13 12 
Total Depreciation and Amortization$2,288 $2,229 $2,230 
(a)The amounts in 2023, 2022 and 2021 include charges of $653 million, $72 million and $56 million, respectively, recorded to Cost of products sold, to adjust estimated future product remediation costs.
(b)The amount in 2022 includes a charge of $54 million, recorded to Cost of products sold, to write down the carrying value of certain fixed assets in the Pharmaceutical Systems unit.
(c)Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense. The amount in 2023 includes a pre-tax gain recognized on the Company's sale of its Surgical Instrumentation platform of approximately $268 million, which is further discussed in Note 2. The amount in 2021 includes a pre-tax charge recorded to Other operating (income) expense, net, related to certain product liability matters of $361 million, as further discussed in Note 6.
Revenues to Unaffiliated Customers and Long-lived Assets Including Property, Plant and Equipment
The table below shows revenues from continuing operations and long-lived assets of continuing operations by geographic area:
(Millions of dollars)202320222021
Revenues
United States$11,113 $10,722 $10,371 
EMEA4,244 4,043 4,548 
Greater Asia2,913 3,047 3,069 
Other1,102 1,058 1,142 
$19,372 $18,870 $19,131 
Long-Lived Assets
United States$35,732 $36,617 $35,896 
EMEA5,317 5,126 5,778 
Greater Asia1,521 1,528 1,607 
Other1,116 1,079 860 
Corporate418 442 465 
$44,104 $44,792 $44,606